AVROBIO, Inc. (AVRO) Financial Statements (2023 and Earlier)

Company Profile

Business Address ONE KENDALL SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments189,567259,682187,043126,302
Cash and cash equivalents189,567259,682187,043126,302
Receivables 4224220
Prepaid expense112973983397
Other current assets1,698271620795
Other undisclosed current assets7,7686,3126,8312,306
Total current assets:199,145267,242195,701130,020
Noncurrent Assets
Property, plant and equipment4,1263,0643,6962,634
Restricted cash and investments492492  
Other noncurrent assets744361,117825
Total noncurrent assets:4,6923,9924,8133,459
TOTAL ASSETS:203,837271,234200,514133,479
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,12416,37514,01710,606
Accounts payable3,4862,6823,9492,784
Accrued liabilities15,63813,69310,0687,822
Deferred rent credit262239  
Total current liabilities:19,38616,61414,01710,606
Noncurrent Liabilities
Long-term debt and lease obligation14,945   
Long-term debt, excluding current maturities14,945   
Liabilities, other than long-term debt30276484689
Deferred rent credit30276484689
Total noncurrent liabilities:14,975276484689
Total liabilities:34,36116,89014,50111,295
Stockholders' equity
Stockholders' equity attributable to parent169,476254,344186,013122,184
Common stock4432
Additional paid in capital553,014518,756330,714193,921
Accumulated deficit(383,542)(264,416)(144,704)(71,739)
Total stockholders' equity:169,476254,344186,013122,184
TOTAL LIABILITIES AND EQUITY:203,837271,234200,514133,479

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(118,841)(120,228)(75,809)(46,243)
Operating loss:(118,841)(120,228)(75,809)(46,243)
Nonoperating income (expense)(285)5162,844(118)
Investment income, nonoperating(224)7192,93497
Other nonoperating expense(61)(203)(90)(53)
Net loss attributable to parent:(119,126)(119,712)(72,965)(46,361)
Preferred stock dividends and other adjustments   (2,243)
Net loss available to common stockholders, diluted:(119,126)(119,712)(72,965)(48,604)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(119,126)(119,712)(72,965)(46,361)
Comprehensive loss, net of tax, attributable to parent:(119,126)(119,712)(72,965)(46,361)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: